Skip to content

Chad May

Chad May

Company: Maverick Therapeutics

Job title: Senior Vice President - Research & Development

Bio:

Chad is the Senior Vice President, Research & Development at Maverick Therapeutics. He is leading preclinical pharmacology and development work on Maverick’s novel T-cell retargeting platform. Chad has more than fifteen years of experience in the biotechnology and pharmaceutical industries. Most recently, he was the Senior Director of Targeted Immunotherapy at Pfizer in the Oncology Research Unit where he spearheaded several T-cell engaging bispecific antibody programs. Prior to that, Chad held roles of increasing responsibility at ImClone Systems, which was acquired by Eli Lilly in 2008. During his time there, Chad was a project team leader for several early stage antibody therapeutics. Chad received his Ph.D. in Immunology from the Weill Cornell Graduate School of Medical Sciences, in a joint program with the Sloan Kettering Institute.

Seminars:

COBRA™: A Novel Conditionally Active T-cell Engager Platform 11:30 am

• Solid tumor directed T-cell engaging bispecifics are limited by target expression on normal tissues • COBRA™ platform is designed to reduce toxicity by restricting T cell engagement to within the tumor microenvironment • Review the pros and cons of solid tumor xenograft models to measure efficacy • Demonstrate potent COBRA™ mediated tumor regressionsRead more

day: Day Two

Chair’s Closing Remarks 5:00 pm

Read more

day: Day One

Chair’s Opening Remarks 8:45 am

Read more

day: Day One

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.